MANAGEMENT STRATEGY OF DIFFERENT HF PHENOTYPES.pptx

How to manage the patients of heart failure is discussed in detail in this slide. Also the various subtypes are dealt separately.

1. MANAGEMENT STRATEGY OF DIFFERENT HF PHENOTYPES

2. HF PHENOTYPES WET PHENOTYPE DE NOVO HF WORSENING HF CARDIORENAL HF FRAIL HF

3. DAPA-HF: Patients in the Dapagliflozin Group Are Still at Risk for CV Death or HFH

4. Contextualizing Risk Among Patients With HF

5. The De Novo Heart Failure Phenotype

6. Definition of De Novo HF Phenotype

7. How to Initiate Therapies in Patient With De Novo HF?

8. Medical Management Strategies for Patients Hospitalized With De Novo HF

9. De Novo HF Recommendations

10. BIG TIP!

11. Oral Therapy Should Be Initiated During Hospitalization and Promptly Optimized Around Discharge

12. Speed Matters: STRONG-HF

13. Speed Matters: Intensive Follow-Up With a Rapid Up-Titration Strategy Can Increase the Proportion of Patients Achieving Optimal GDMT

14. Optimized Treatment Sequencing Reduces a Larger Number of Deaths and HHF Compared With Conventional Sequencing

15. 20% Reduction in Risk of Death/HF Hospitalisation, ~42% Reduction in Risk of Death, and an Increase of > 5 Years in Life Expectancy

16. Management and Prevention of Worsening/Advanced Heart Failure

17. WORSENING HF PHENOTYPE

18. Vericiguat Stimulates sGC

19. VICTORIA Trial: Targeting the sGC Pathway in Patients With Worsening HFrEF

20. Indication-Corrected Adherence Was Very High in VICTORIA

21. VICTORIA Showed Significant Reduction in the Annualized Absolute Rate of Time to HFH or CV Death by 4.2 Events/100 PY

22. Subgroup Analysis of Primary Endpoint: ITT

23. NT-proBNP and Clinical Outcomes

24. Contemporary HF Outcome Trials: Secondary Endpoint, Absolute Rate Reduction

25. Underutilization of GDMT

26. VICTORIA Demonstrated Similar Rates of AEs and SAEs Across Both Study Arms

27. No Excessive Blood Pressure Reductions Were Observed With Vericiguat in Patients at Risk for Hypotension

28. Impact of Vericiguat on Renal Function Trajectories Was Similar to that of Placebo

29. Incidence of Hyperkalemia Was Similar Between Treatment Arms, Even in Patients With Low Renal Function

30. Vericiguat as Part of a Multidrug Approach Following a Worsening HF Event

31. Recent Years Have Brought New Guidance and Recommendations in HF Across International Societies

32. ESC-HFA Consensus Statement: Treatment And Prevention Of Worsening HF

33. Discontinuation of GDMT in 23% to 42% Following Hospitalization

34. Hospitalization: Reflects Patient Risk + Opportunity

35. MANAGEMENT OF HF ACCORDING TO PHENOTYPES

36. HFpEF Understanding the Optimal Treatment Algorithm With Supporting Data

37. MANAGEMENT OF HFPEF

38. HFrEF: Pathophysiology Makes Sense

39. The Interplay of Comorbidities

40. HFpEF Therapies: The Bad, the Promising, and the Hopeful

41. SGLT2 inhibitors

42. Spironolactone

43. Spironolactone

44. Angiotensin Receptor-Neprilysin Inhibitors

45. Angiotensin Receptor Blockers

46. Exercise/Weight Loss Works!

47. GLP-1 Receptor Agonists

48. GLP-1 RA in HFpEF

49. GLP-1 RA in HFpEF

50. Interatrial Shunt Devices

51. Interatrial Shunt Devices

52. REDUCE-LAP HF II

53. REDUCE-LAP HF II

54. HOPE EXISTS FOR HFPEF

55. Advances in Chronic Heart Failure Therapies: Beyond Drugs to Devices

56. HF THERAPY:BEYOND DRUGS

57. Filling the Gap

58. Filling the Gap

59. Filling the Gap

60. Effect of Baroreflex Activation on Sympathetic Tone

61. Barostimulation Therapy

62. Durable Improvement in Quality of Life (MLWHF)

63. Cardiac Contractility Modulation

64. FIX-HF-5 and FIX-HF-5C Cardiovascular Death and HF Hospitalizations

65. Sleep Disordered Breathing Is Strongly Associated With Increased Mortality in HF Patients

66. Transvenous Phrenic Nerve Stimulation

67. Volume Redistribution Concept: Splanchnic Nerve Modulation [1-3]

68. Volume Redistribution Concept: Splanchnic Nerve Modulation [1-3]

69. Primary Efficacy Endpoint Met With Significantly Reduced Heart Failure Hospitalization

70. Remote Monitoring

71. Remote Monitoring

72. Classification of MR Primary (Degenerative) and Secondary (Functional)

73. Primary Effectiveness Endpoint All Hospitalizations for HF Within 24 Months

74. The Carillon Mitral Contour System